The PRESS Pad

A personalised mRNA cancer therapy developed by Moderna and Merck has delivered positive Phase 3 results in patients with high-risk melanoma. Called intismeran autogene, the experimental treatment is individually designed using mutations from each patient's tumour and given alongside the immunotherapy Keytruda. Here's how it works, what researchers have found so far, and why access and cost remain major questions for India. A cancer treatment designed individually around the